Concepedia

H. Kantarjian

HK

57

Publications

4.5K

Citations

30

H-Index

1986

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Princess Margaret Cancer Centre

Bristol-Myers Squibb (United States)

Cornell University

South Australia Pathology

H. Kantarjian is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and oncology.

Top concepts

Publications per year

1986–2024

57

Publications

57

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

MJ Keating, H. Kantarjian, Moshe Talpaz et al. · Blood · 1989 · 455 citations · Full text

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Richard A. Larson, Andreas Hochhaus, Timothy P. Hughes et al. · Leukemia · 2012 · 437 citations

, , +8

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger et al. · Leukemia · 2008 · 352 citations

, , +8

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Francis J. Giles, H. Kantarjian, Steve Kornblau et al. · Cancer · 2001 · 280 citations

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Michael J. Keating, H. Kantarjian, S O'Brien et al. · Journal of Clinical Oncology · 1991 · 249 citations

, , +18

Rows per page

1–5 of 57